Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
Daily oral upadacitinib 30 mg and ABBV-599 high dose (elsubrutinib 60 mg QD + upadacitinib 30 mg) were effective in multiple outcome measures including disease activity, flares, time to first flare, and joint counts.
Lupus Sci. Med 2023;10:e000907 doi 10.1136/lupus-2023-000907
This retrospective study by Neupane, et al. compared belimumab and anifrolumab efficacy at 52 weeks in SLE patients. It concluded that belimumab and anifrolumab have equal efficacy, but further studies would be needed for specific patient demographics.
